vs
Side-by-side financial comparison of BRANDYWINE REALTY TRUST (BDN) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
BRANDYWINE REALTY TRUST is the larger business by last-quarter revenue ($127.0M vs $70.6M, roughly 1.8× Viridian Therapeutics, Inc.\DE). BRANDYWINE REALTY TRUST runs the higher net margin — -38.4% vs -49.0%, a 10.6% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 4.5%).
Brandywine Realty Trust is a Philadelphia-based real estate investment trust (REIT) that invests in office buildings in Philadelphia, Washington, D.C., and Austin, Texas.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
BDN vs VRDN — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $127.0M | $70.6M |
| Net Profit | $-48.8M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 1.2% | -56.7% |
| Net Margin | -38.4% | -49.0% |
| Revenue YoY | 4.5% | 81958.1% |
| Net Profit YoY | -80.4% | 54.9% |
| EPS (diluted) | $-0.28 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $127.0M | — | ||
| Q4 25 | $121.0M | — | ||
| Q3 25 | $121.4M | $70.6M | ||
| Q2 25 | $120.6M | — | ||
| Q1 25 | $121.5M | — | ||
| Q4 24 | $121.9M | — | ||
| Q3 24 | $131.8M | — | ||
| Q2 24 | $125.3M | — |
| Q1 26 | $-48.8M | — | ||
| Q4 25 | $-36.7M | — | ||
| Q3 25 | $-25.9M | $-34.6M | ||
| Q2 25 | $-88.7M | — | ||
| Q1 25 | $-27.0M | — | ||
| Q4 24 | $-44.5M | — | ||
| Q3 24 | $-165.2M | — | ||
| Q2 24 | $30.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | 61.3% | — | ||
| Q3 25 | 62.6% | — | ||
| Q2 25 | 62.4% | — | ||
| Q1 25 | 60.8% | — | ||
| Q4 24 | 61.2% | — | ||
| Q3 24 | 64.9% | — | ||
| Q2 24 | 63.1% | — |
| Q1 26 | 1.2% | — | ||
| Q4 25 | 22.8% | — | ||
| Q3 25 | 20.8% | -56.7% | ||
| Q2 25 | -34.3% | — | ||
| Q1 25 | 12.5% | — | ||
| Q4 24 | 18.0% | — | ||
| Q3 24 | -7.2% | — | ||
| Q2 24 | 15.5% | — |
| Q1 26 | -38.4% | — | ||
| Q4 25 | -30.3% | — | ||
| Q3 25 | -21.3% | -49.0% | ||
| Q2 25 | -73.5% | — | ||
| Q1 25 | -22.2% | — | ||
| Q4 24 | -36.5% | — | ||
| Q3 24 | -125.4% | — | ||
| Q2 24 | 24.1% | — |
| Q1 26 | $-0.28 | — | ||
| Q4 25 | $-0.21 | — | ||
| Q3 25 | $-0.15 | — | ||
| Q2 25 | $-0.51 | — | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $-0.25 | — | ||
| Q3 24 | $-0.96 | — | ||
| Q2 24 | $0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.2M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $503.0M |
| Total Assets | $3.6B | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $36.2M | — | ||
| Q4 25 | $32.3M | — | ||
| Q3 25 | $75.5M | $490.9M | ||
| Q2 25 | $122.6M | — | ||
| Q1 25 | $29.4M | — | ||
| Q4 24 | $90.2M | — | ||
| Q3 24 | $36.5M | — | ||
| Q2 24 | $30.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.2B | — |
| Q1 26 | — | — | ||
| Q4 25 | $792.7M | — | ||
| Q3 25 | $841.5M | $503.0M | ||
| Q2 25 | $879.8M | — | ||
| Q1 25 | $993.6M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.3B | — |
| Q1 26 | $3.6B | — | ||
| Q4 25 | $3.6B | — | ||
| Q3 25 | $3.3B | $577.1M | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.6B | — | ||
| Q2 24 | $3.8B | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.23× | — | ||
| Q3 25 | 2.70× | — | ||
| Q2 25 | 2.63× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | 2.13× | — | ||
| Q3 24 | 2.06× | — | ||
| Q2 24 | 1.73× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $116.7M | — | ||
| Q3 25 | $47.5M | $-84.6M | ||
| Q2 25 | $34.4M | — | ||
| Q1 25 | $6.3M | — | ||
| Q4 24 | $181.1M | — | ||
| Q3 24 | $52.2M | — | ||
| Q2 24 | $48.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDN
| Rents | $120.7M | 95% |
| Third party management fees, labor reimbursement and leasing | $4.7M | 4% |
VRDN
Segment breakdown not available.
